Drug Discovery World

JULY 25, 2023

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. months and the CR rate in those receiving placebo was 55%, with a median duration of 12.4

FDA Approval 130

FDA Approval FDA Clinical Trials Trials 130

Drug Discovery World

MAY 15, 2023

The US Food and Drug Administration (FDA) has given the go-ahead to CytoAgents to initiate a US Phase Ib/IIa clinical trial investigating CTO1681 for cytokine release syndrome (CRS) in lymphoma patients receiving CAR-T cell therapy. The company has also announced the initial closing of its second equity round of financing. “We

FDA Approval 130

FDA Approval FDA Clinical Trials Therapies 130

Drug Discovery World

JUNE 12, 2023

The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

FDA Approval 130

FDA Approval FDA Trials Clinical Trials 130

Drug Discovery World

SEPTEMBER 20, 2022

SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). Nearly half of patients who do not receive treatment die within five years of symptom onset.

FDA Approval 130

FDA Approval FDA Therapies Hospitals 130

Drug Discovery World

DECEMBER 11, 2023

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology.

FDA Approval 130

FDA Approval Therapies FDA Disease 130

Drug Discovery World

JANUARY 23, 2023

As an FDA-approved oral drug, the side-effects of cladribine are quite manageable and it has been well evaluated for pharmacokinetics. Additionally, the clinical trial period will be considerably shorter than that required for new drug development. GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 130

FDA Approval FDA Drugs Pharmacokinetics 130

PLOS: DNA Science

MARCH 28, 2024

FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. The New Drug Duvyzat (givinostat), a type of drug called an HDAC inhibitor, has been in clinical trials to treat cancers and other disorders of the blood, Crohn’s disease, and a form of juvenile arthritis.

FDA Approval 75

FDA Approval Treatment FDA DNA 75

Drug Discovery World

APRIL 3, 2023

This year, the team will launch a combined Phase I and IIa trial of R805/CX-011 for the treatment of osteoarthritis in patients in collaboration with the start-up Carthronix. They think the drug has the potential to delay or even reduce the need for joint replacement surgery, the only existing FDA-approved therapy for osteoarthritis.

Clinical Trials 130

Clinical Trials Trials FDA Approval Drugs 130

Drug Discovery World

SEPTEMBER 12, 2024

Childhood cancers often have a different biology than those in adults, yet targeted treatment options are mostly based on adult therapies. In addition, small patient populations make clinical trials difficult and reduce incentives for investment.

Research 147

Research Small Molecule FDA Approval Drugs 147

BioPharma Drive: Drug Pricing

JUNE 4, 2024

A group of independent experts wasn't convinced by clinical trial data from company Lykos Therapeutics, which is seeking FDA approval of MDMA-assisted treatment for post-traumatic stress disorder.

FDA 131

FDA FDA Approval Clinical Trials Therapies 131

Drug Discovery World

SEPTEMBER 13, 2022

Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours. The post New treatment hope for patients with rare tumours appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment FDA Approval Clinical Trials Hospitals 130

Drug Discovery World

JUNE 16, 2023

Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation for AstraZeneca UK, and an update to the HER2 Breast Cancer Testing Guidelines.

FDA Approval 130

FDA Approval Clinical Trials FDA Drugs 130

Drug Discovery World

OCTOBER 18, 2023

We’re beginning to see their potential come to fruition, with the FDA having approved three treatments as of January 2023 — for retinal dystrophy 1 spinal muscular atrophy, 2 and haemophilia B. Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas.

Therapies 162

Therapies Clinical Trials FDA Approval Virus 162

Conversations in Drug Development Trends

FEBRUARY 26, 2024

With the necessary prioritization of various factors when designing your clinical trial, the patient experience can be overlooked or improperly addressed in study design. There are endpoints that can be easily measured, that are already standardized, and they are FDA-approved,” says Dr. Ojeda.

Clinical Trials 59

Clinical Trials Trials Disease FDA Approval 59

Drug Discovery World

JUNE 6, 2024

months after initial treatment. The global Phase III clinical trial is being led by University College London Hospitals NHS Foundation Trust in the UK and will include around 1,100 people. Ultimately it will contribute to survival rates improving continually over the next decades and more.” It showed that the 2.5-year

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

The Pharma Data

JANUARY 21, 2021

The shot is given as two intramuscular injections in the buttocks once a month at a specialist clinic. Today’s FDA approval of Cabenuva represents a shift in the way HIV is treated, offering people living with HIV a completely new approach to care,” said Lynn Baxter, Head of North America, ViiV Healthcare. clinical practices.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

JULY 8, 2021

The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen below ( italics to note updated language). ADUHELM is indicated for the treatment of Alzheimer’s disease. Alfred Sandrock, Jr., INDICATION.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

NOVEMBER 27, 2020

FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma. the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

Drug Discovery World

MARCH 1, 2024

This is the first time the FDA has used the amended procedures for withdrawal of accelerated approval that were enacted in 2023, as part of the Food and Drug Omnibus Report Act of 2022 (FDORA). Oncopeptides was required to conduct the OCEAN trial as a post-approval requirement under the accelerated approval programme.

FDA 130

FDA Clinical Trials FDA Approval Trials 130

Drug Discovery World

JULY 31, 2023

President and Chief Executive Officer Christopher Viehbacher said: “In the second quarter, Biogen continued to advance ground-breaking science with the FDA approval of two first-in-class therapies for Alzheimer’s disease and ALS, while also delivering on our base business expectations. Biogen’s business is in transition.

FDA Approval 130

FDA Approval FDA Clinical Trials Disease 130

Drug Discovery World

DECEMBER 22, 2023

There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer.

FDA Approval 130

FDA Approval Drugs Clinical Trials FDA 130

The Pharma Data

AUGUST 10, 2020

Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy available for the rare hereditary genetic condition in US and the second overall to be approved for the disease. with placebo.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

The Pharma Data

OCTOBER 29, 2021

Novartis blazoned moment that the US Food and Drug Administration (FDA) approved Scemblix ® (asciminib) for the treatment of habitual myeloid leukemia (CML) in two distinct suggestions. In cases with Ph CML-CP who had endured resistance or dogmatism to at least two TKIs, the ASCEMBL trial showed that1-3.Scemblix

FDA Approval 52

FDA Approval FDA Treatment Trials 52

Drug Discovery World

APRIL 4, 2023

Orserdu (elacestrant), Stemline Therapeutics The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer was approved in the US in February. The drug was granted orphan drug designation by the FDA in May 2021. Here’s a summary.

FDA 130

FDA FDA Approval Small Molecule Therapies 130

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. The speed and rigor with which Veklury has been developed and approved in the U.S.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

Drug Discovery World

DECEMBER 22, 2022

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen). . It had already received FDA approval for the United States in March of this year.

Clinical Trials 130

Clinical Trials FDA Approval Drugs Hospitals 130

Drug Discovery World

NOVEMBER 23, 2023

Minoryx has announced enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in the US Phase III clinical trial, CALYX. CALYX has been designed as a Phase III trial to confirm the disease modifying potential of leriglitazone that we detected in the previous ADVANCE and NEXUS trials,” said Arun Mistry, CMO, Minoryx. “The

Trials 130

Trials Clinical Trials FDA Approval FDA 130

The Pharma Data

JUNE 26, 2023

FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata Pfizer Inc. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. Source link: [link]

FDA Approval 40

FDA Approval FDA Clinical Trials Treatment 40

Drug Discovery World

MARCH 29, 2024

FDA approves Covid-19 mAb for emergency use The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to half-life extended monoclonal antibody (mAb) Pemgarda (pemivibart, or VYD222) for the pre-exposure prophylaxis of Covid-19. Could a novel psychedelic treat alcohol use disorder?

FDA Approval 130

FDA Approval FDA Drugs Trials 130

Drug Target Review

FEBRUARY 21, 2024

This is a time when several promising treatments – including mRNA vaccines, BiTE therapies and CAR-T cell therapy, are essentially in competition with each other – they all have a common goal of treating the same disease, but they are approaching the objective from different angles.

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Discovery World

SEPTEMBER 7, 2023

1 There are a number of challenges faced in paediatric R&D, including the fact that the overall group includes five different age groups, the need for specific biomarkers, the extra length of time needed for trials, and the ethical concerns of conducting clinical trials in children.

Clinical Trials 147

Clinical Trials Trials Drugs DNA 147

Drug Discovery World

SEPTEMBER 2, 2024

Emphasis on manufacturing Experts were unanimous in their view of how far the cell & gene therapy (CGT) sector has come and the milestones achieved in both 2023 and early 2024, most referencing the first FDA-approved CRISPR therapeutic and the impact this will have on in-progress CRISPR clinical trials.

Therapies 147

Therapies Clinical Trials Trials FDA Approval 147

Drug Discovery World

FEBRUARY 14, 2024

We believe that AlphaMedix has potential to demonstrate substantial benefit over currently FDA approved PRRT with beta-particle emitters for patients with metastatic or inoperable SSTR-expressing GEP-NETs,” said Ebrahim Delpassand, Chairman and Chief Executive Officer of RadioMedix.

Therapies 130

Therapies FDA Approval FDA Clinical Trials 130

Drug Discovery World

MARCH 12, 2024

Advancements in antibody-drug conjugates are also expected, enhancing targeted delivery for cancer treatments.” Carole Nicco, CSO, BioSenic “mAb immunotherapy is the most widely used approach and has achieved tremendous success. Other ACTs such as TIL, TCR, NK cell, Treg, and MDSC therapies are now emerging.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

Drug Discovery World

NOVEMBER 14, 2023

“The FDA remains deeply committed in our efforts to help facilitate the development and approval of safe and effective therapies for patients with rare diseases,” said Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research. Without treatment, cTTP is ultimately fatal.

Therapies 130

Therapies FDA Approval Protein Production FDA 130

Drug Discovery World

MAY 1, 2024

We also predict that the number of new candidate drugs being identified or entering clinical trials that are mAbs will also increase. High response rates have been reported for both mAb and CAR T-cell cancer therapy; however, treatment refractoriness and disease relapse still occur and represent an ongoing clinical challenge.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S.

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52